EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cambium Bio's enterprise value is A$3.11 Mil.
Cambium Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil. Therefore, Cambium Bio's EV-to-Revenue for today is .
The historical rank and industry rank for Cambium Bio's EV-to-Revenue or its related term are showing as below:
During the past 10 years, the highest EV-to-Revenue of Cambium Bio was 85.21. The lowest was -0.24. And the median was 15.35.
ASX:CMB's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.565 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-20), Cambium Bio's stock price is A$0.005.
Cambium Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, Cambium Bio's PS Ratio for today is .
Cambium Bio EV-to-Revenue Historical Data
The historical data trend for Cambium Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cambium Bio's EV-to-Revenue
For the Biotechnology subindustry, Cambium Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cambium Bio's EV-to-Revenue falls into.
Cambium Bio's current Enterprise Value is A$3.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio's share price for today is A$0.005.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cambium Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:CMB has been successfully added to your 